Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for IIH headache sufferers: migraine drug tested in landmark trial

NCT ID NCT07645833

Symptom relief Sponsor: Rigmor Højland Jensen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether eptinezumab, a drug used for migraines, can reduce the number of headache days in adults with idiopathic intracranial hypertension (IIH), a condition where high fluid pressure around the brain causes severe headaches. About 96 women aged 18-55 with chronic headaches will receive either the drug or a placebo. The goal is to see if the drug lowers monthly moderate-to-severe headache days and improves quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 96 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female, aged 18 to 55 years * Diagnosis of idiopathic intracranial hypertension (IIH) or IIH without papilledema * Chronic headache associated with IIH * At least 15 headache days per monthduring the screening period * At least 8 migraine-like headache days per month during the screening period * Use of effective contraception througout the trial period and for at least 5 months after last administration of study drug Exclusion Criteria: * Non-compliance with headache diary completion during screening, defined as less than 80% of the days reported * Contraindications to receiving eptinezumab according to the Summary of Product Characteristics * Previous or current treatment with anti-CGRP monoclonal antibodies within 5 half-lives * Previous insufficient or non-effective treatment with eptinezumab * Pregnancy, breastfeeding, or planning pregnancy during the sudy period

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Idiopathic intracranial hypertension (IIH) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pseudotumor cerebri headache disorder prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Idiopathic intracranial hypertension (IIH)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.